Option Care Health Files Definitive Proxy Statement

Ticker: OPCH · Form: DEF 14A · Filed: Apr 3, 2024 · CIK: 1014739

Sentiment: neutral

Topics: Option Care Health, DEF 14A, Naven Health, Infusion Services, Proxy Statement

TL;DR

<b>Option Care Health details 2023 achievements including Naven Health launch and expansion of infusion services.</b>

AI Summary

Option Care Health, Inc. (OPCH) filed a Proxy Statement (DEF 14A) with the SEC on April 3, 2024. Option Care Health served over 270,000 unique patients in 2023 with a team of over 7,500 members, including 4,500 clinicians. Launched Naven Health, an infusion nursing platform with over 1,500 clinical professionals. Expanded ambulatory infusion suite and advanced practitioner footprint to over 164 centers and 660 chairs. Advanced use of data analytics, AI, and machine learning to optimize operations and revenue cycle management. Deepened partnerships with biopharmaceutical companies, launching new therapies and expanding network services.

Why It Matters

For investors and stakeholders tracking Option Care Health, Inc., this filing contains several important signals. The company highlights its significant patient reach and clinician base, emphasizing its role in the home and alternate site infusion industry. Strategic initiatives like Naven Health and technology investments underscore a focus on growth and operational efficiency in a competitive healthcare landscape.

Risk Assessment

Risk Level: low — Option Care Health, Inc. shows low risk based on this filing. The filing is a routine DEF 14A proxy statement, which typically contains standard disclosures about executive compensation, board matters, and annual meeting information, posing no immediate new risks.

Analyst Insight

Review the detailed executive compensation and board proposals to understand potential changes in governance and management incentives.

Key Numbers

Key Players & Entities

FAQ

When did Option Care Health, Inc. file this DEF 14A?

Option Care Health, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 3, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Option Care Health, Inc. (OPCH).

Where can I read the original DEF 14A filing from Option Care Health, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Option Care Health, Inc..

What are the key takeaways from Option Care Health, Inc.'s DEF 14A?

Option Care Health, Inc. filed this DEF 14A on April 3, 2024. Key takeaways: Option Care Health served over 270,000 unique patients in 2023 with a team of over 7,500 members, including 4,500 clinicians.. Launched Naven Health, an infusion nursing platform with over 1,500 clinical professionals.. Expanded ambulatory infusion suite and advanced practitioner footprint to over 164 centers and 660 chairs..

Is Option Care Health, Inc. a risky investment based on this filing?

Based on this DEF 14A, Option Care Health, Inc. presents a relatively low-risk profile. The filing is a routine DEF 14A proxy statement, which typically contains standard disclosures about executive compensation, board matters, and annual meeting information, posing no immediate new risks.

What should investors do after reading Option Care Health, Inc.'s DEF 14A?

Review the detailed executive compensation and board proposals to understand potential changes in governance and management incentives. The overall sentiment from this filing is neutral.

How does Option Care Health, Inc. compare to its industry peers?

Option Care Health operates in the home and alternate site infusion industry, providing specialized healthcare services to patients requiring complex therapies outside traditional hospital settings.

Are there regulatory concerns for Option Care Health, Inc.?

The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring public disclosure of corporate governance and shareholder matters.

Industry Context

Option Care Health operates in the home and alternate site infusion industry, providing specialized healthcare services to patients requiring complex therapies outside traditional hospital settings.

Regulatory Implications

The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring public disclosure of corporate governance and shareholder matters.

What Investors Should Do

  1. Analyze the proposals for the annual meeting, including any director elections or executive compensation plans.
  2. Review the detailed financial information and any forward-looking statements provided in the full filing.
  3. Assess the company's strategic initiatives and their potential impact on future performance.

Key Dates

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document. Specific comparative data from a previous filing is not detailed in this excerpt.

Filing Stats: 4,369 words · 17 min read · ~15 pages · Grade level 14 · Accepted 2024-04-03 16:06:46

Key Financial Figures

Filing Documents

Executive Compensation Tables

Executive Compensation Tables 59 CEO Pay Ratio 70 Pay-Versus-Performance 71 Proposal 3: Advisory Vote to Approve Executive Compensation 75 Proposal 4: Approval of Amended and Restated 2018 Equity Incentive Plan 76 Equity Compensation Plan Information 87

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 88 General Information About the Annual Meeting 90 Additional Information 94 Appendix A: Non-GAAP Financial Measures A-1 Appendix B: Option Care Health, Inc. Amended and Restated 2018 Equity Incentive Plan B-1 The Board of Directors (the "Board") of Option Care Health, Inc., a Delaware corporation ("we," "us," "our," or "Option Care Health"), is soliciting proxies for use at our 2024 Annual Meeting of Stockholders, including any postponements or adjournments thereof (the "Annual Meeting"). On April 7, 2015, HC Group Holdings II, Inc. ("HC II") and its sole shareholder, HC Group Holdings I, LLC ("HC I"), collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co ("Walgreens") and became a stand-alone, privately-held company (the "Walgreens Separation"). On August 6, 2019, the privately-held HC I and HC II completed a transaction (the "BioScrip Merger") to merge with and into a wholly-owned subsidiary of BioScrip, Inc., a publicly-traded, national provider of infusion and home care management solutions ("BioScrip"). Following the closing of the BioScrip Merger, the now publicly-traded, combined companies were rebranded as "Option Care Health, Inc." These materials were first sent or made available to stockholders on April 3, 2024. TABLE OF CONTENTS Proxy Summary This summary highlights certain information contained in this Proxy Statement. This summary does not contain all the information that you should consider, and you should read the entire Proxy Statement before voting. For more complete information regarding our performance in the fiscal year ended December 31, 2023, please review our Annual Report on Form 10-K for the year ended December 31, 2023 that accompanied this Proxy Statement. Ways to Vote PHONE In order to do so, please follow the instructions shown on your Notice or Proxy Card. INTERNET In order to do so, please follow the instru

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing